Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults

NCT05032859 is registered in ClinicalTrials.gov with Organon and Co as lead sponsor.

NCT NCT05032859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05032859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults
Lead sponsor
Organon and Co
Phase
Phase 3
Overall status
Completed
Start date
September 23, 2021
Completion date
February 8, 2023
Enrollment
406 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis